COVID-19 Vaccination and Non-COVID-19 Mortality Risk - Seven Integrated Health Care Organizations, United States, December 14, 2020-July 31, 2021
- PMID: 34710075
- PMCID: PMC8553028
- DOI: 10.15585/mmwr.mm7043e2
COVID-19 Vaccination and Non-COVID-19 Mortality Risk - Seven Integrated Health Care Organizations, United States, December 14, 2020-July 31, 2021
Abstract
By September 21, 2021, an estimated 182 million persons in the United States were fully vaccinated against COVID-19.* Clinical trials indicate that Pfizer-BioNTech (BNT162b2), Moderna (mRNA-1273), and Janssen (Johnson & Johnson; Ad.26.COV2.S) vaccines are effective and generally well tolerated (1-3). However, daily vaccination rates have declined approximately 78% since April 13, 2021†; vaccine safety concerns have contributed to vaccine hesitancy (4). A cohort study of 19,625 nursing home residents found that those who received an mRNA vaccine (Pfizer-BioNTech or Moderna) had lower all-cause mortality than did unvaccinated residents (5), but no studies comparing mortality rates within the general population of vaccinated and unvaccinated persons have been conducted. To assess mortality not associated with COVID-19 (non-COVID-19 mortality) after COVID-19 vaccination in a general population setting, a cohort study was conducted during December 2020-July 2021 among approximately 11 million persons enrolled in seven Vaccine Safety Datalink (VSD) sites.§ After standardizing mortality rates by age and sex, this study found that COVID-19 vaccine recipients had lower non-COVID-19 mortality than did unvaccinated persons. After adjusting for demographic characteristics and VSD site, this study found that adjusted relative risk (aRR) of non-COVID-19 mortality for the Pfizer-BioNTech vaccine was 0.41 (95% confidence interval [CI] = 0.38-0.44) after dose 1 and 0.34 (95% CI = 0.33-0.36) after dose 2. The aRRs of non-COVID-19 mortality for the Moderna vaccine were 0.34 (95% CI = 0.32-0.37) after dose 1 and 0.31 (95% CI = 0.30-0.33) after dose 2. The aRR after receipt of the Janssen vaccine was 0.54 (95% CI = 0.49-0.59). There is no increased risk for mortality among COVID-19 vaccine recipients. This finding reinforces the safety profile of currently approved COVID-19 vaccines in the United States.
Conflict of interest statement
All authors have completed and submitted the International Committee of Medical Journal Editors form for disclosure of potential conflicts of interest. Runxin Huang reports support for attending meetings or travel from Dynavax Technologies. Nicola P. Klein reports institutional support from Pfizer, Sanofi Pasteur, Merck, GlaxoSmithKline, and Protein Science (now Sanofi Pasteur to support vaccine studies). Elizabeth G. Liles reports research contracts from the National Human Genome Research Institute and Pfizer. Kerresa Morrissette reports research contracts from the National Institutes of Health, GlaxoSmithKline, and Merck Sharp & Dohme Corporation, outside the submitted work. No other potential conflicts of interest were disclosed.
Similar articles
-
Use of COVID-19 Vaccines After Reports of Adverse Events Among Adult Recipients of Janssen (Johnson & Johnson) and mRNA COVID-19 Vaccines (Pfizer-BioNTech and Moderna): Update from the Advisory Committee on Immunization Practices - United States, July 2021.MMWR Morb Mortal Wkly Rep. 2021 Aug 13;70(32):1094-1099. doi: 10.15585/mmwr.mm7032e4. MMWR Morb Mortal Wkly Rep. 2021. PMID: 34383735 Free PMC article.
-
Comparative Effectiveness of Moderna, Pfizer-BioNTech, and Janssen (Johnson & Johnson) Vaccines in Preventing COVID-19 Hospitalizations Among Adults Without Immunocompromising Conditions - United States, March-August 2021.MMWR Morb Mortal Wkly Rep. 2021 Sep 24;70(38):1337-1343. doi: 10.15585/mmwr.mm7038e1. MMWR Morb Mortal Wkly Rep. 2021. PMID: 34555004 Free PMC article.
-
COVID-19 Vaccination Coverage Among Insured Persons Aged ≥16 Years, by Race/Ethnicity and Other Selected Characteristics - Eight Integrated Health Care Organizations, United States, December 14, 2020-May 15, 2021.MMWR Morb Mortal Wkly Rep. 2021 Jul 16;70(28):985-990. doi: 10.15585/mmwr.mm7028a1. MMWR Morb Mortal Wkly Rep. 2021. PMID: 34264911 Free PMC article.
-
COVID-19 vaccines: comparison of biological, pharmacological characteristics and adverse effects of Pfizer/BioNTech and Moderna Vaccines.Eur Rev Med Pharmacol Sci. 2021 Feb;25(3):1663-1669. doi: 10.26355/eurrev_202102_24877. Eur Rev Med Pharmacol Sci. 2021. PMID: 33629336 Review.
-
COVID-19 vaccination among pregnant people in the United States: a systematic review.Am J Obstet Gynecol MFM. 2022 Jul;4(4):100616. doi: 10.1016/j.ajogmf.2022.100616. Epub 2022 Mar 10. Am J Obstet Gynecol MFM. 2022. PMID: 35283351 Free PMC article. Review.
Cited by
-
Comparison of Transient and Persistent Adverse Events After COVID-19 Vaccination: A Retrospective Analysis.Cureus. 2024 Jun 28;16(6):e63410. doi: 10.7759/cureus.63410. eCollection 2024 Jun. Cureus. 2024. PMID: 39070394 Free PMC article.
-
Association between mRNA COVID-19 vaccine boosters and mortality in Japan: The VENUS study.Hum Vaccin Immunother. 2024 Dec 31;20(1):2350091. doi: 10.1080/21645515.2024.2350091. Epub 2024 May 17. Hum Vaccin Immunother. 2024. PMID: 38757631 Free PMC article.
-
Willingness-to-pay for COVID-19 vaccine in ten low-middle-income countries in Asia, Africa and South America: A cross-sectional study.Narra J. 2022 Apr;2(1):e74. doi: 10.52225/narra.v2i1.74. Epub 2022 Apr 1. Narra J. 2022. PMID: 38450393 Free PMC article.
-
The importance of falsification endpoints in observational studies of vaccination to prevent severe disease: A critique of a harm-benefit analysis of BNT162b2 vaccination of 5- to 11-year-olds.Epidemiol Infect. 2024 Feb 16;152:e51. doi: 10.1017/S0950268824000098. Epidemiol Infect. 2024. PMID: 38361448 Free PMC article.
-
Early Mortality After the First Dose of COVID-19 Vaccination: A Target Trial Emulation.Clin Infect Dis. 2024 Mar 20;78(3):625-632. doi: 10.1093/cid/ciad604. Clin Infect Dis. 2024. PMID: 38319989 Free PMC article.
References
-
- Food and Drug Administration. Janssen COVID-19 vaccine Emergency Use Authorization letter. Silver Spring, MD: US Department of Health and Human Services, Food and Drug Administration; 2021. https://www.fda.gov/media/146303/download
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous